| | Good morning, 360! | Don’t forget to join us today for LIVE trading in the Market Master’s Room. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | RGLS - Up over 23% in pre after announcing positive Phase 1b results for treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | EPOW - Up over 35% in pre after its Lithium-Ion battery patent has been granted key funding in Guizhou Province | ALNY - Up over 30% in the pre-market after reporting positive Phase 3 results for Vutrisan, reducing mortality and recurrent cardiovascular events | | *sponsored by Shore Thing Media | Cyber security stocks have been on fire lately 🔥. | Just look at the price charts of leaders like PANW, FTNT, and CRWD, or even my favorite way to trade the sector, a cleverly named ETF called “HACK.” | When the whole sector is hot, I think it increases your odds of success. | Enter our hot stock idea for today: Hub Cyber Security (HUBC). | HUBC is a smaller stock that has shown some incredible moves lately. | In the chart below, I circled the three recent times that HUBC made a breakout over the 20-hour moving average. | The first time, it led to an incredible 200%+ move over a few days. | After that, we had a “fakeout” that attempted to break out but then fizzled. | Right now, we are seeing the early stages of another attempt at a breakout… | | You can see that the stock had a nice 20% spike on good volume around a week ago and has switched from a purple downtrend to “GO” signals and a strong uptrend. | Looking at price levels, I like to use closing prices either under the 20-hour moving average or below the recent “GO” signal (around $.75) as spots where I would look to protect my capital with a stop loss. | When I am betting on an uptrend to work, it needs to happen pretty quickly, or else I want to go to the sidelines. | If this idea does start to work out, I would keep an eye on the $1 level, which always seems to be a line of resistance (or support) for small stocks — which is about 20% higher than current levels. | Of course, I’ll never try to tell you what to do with a trade, but when I trade smaller stocks like this, I always want to use what I call “2 to 1” risk/reward. | You can read more about this on my hot stock page. And as always make sure to do your own due diligence as trading is risky and nothing is guaranteed. | *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
| | HOTLIST🔥 | RGLS - Up over 23% in pre after announcing positive Phase 1b results for treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Regulus Therapeutics Inc. (RGLS) is a clinical-stage biopharmaceutical company that focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. | In the pre-market this morning, the company announced positive Phase 1b results for treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). | Highlights include: | -Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses | -Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo | -Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg | The stock traded up over 23% in the pre-market in reaction to the positive Phase 1b results. | | The $3.02 area acted as support in the pre-market and now becomes a potential resistance level. | Above it, targets to the upside are $3.20, $3.30 and then the pre-market high at $3.56. Beyond that, $3.79, $4.30, $5.12 and $6 come into play. | Below, $3.02, targets to the downside are $2.70, $2.66 and then a gap fill at $2.51. | | | | EPOW - Up over 35% in pre after its Lithium-Ion battery patent has been granted key funding in Guizhou Province | Sunrise New Energy Co. Ltd. (EPOW) engages in the manufacture and sale of graphite anode material for EVs and other lithium-ion batteries. | In the after hours Friday, the company announced that it has been selected for the "2024 Guizhou Provincial Key Projects for Promoting the Utilization of Intellectual Property" funding list. This recognition was released by the Guizhou Provincial Market Supervision Administration (Intellectual Property Office) on June 17th, marking a significant milestone for the Company. | This patent solves the critical and common technical issue of balancing power performance and initial efficiency. It enhances the initial efficiency and power performance of graphite composite materials, providing an excellent solution for the next generation of high-energy-density fast-charging batteries, which has vast market potential. | Since the sales of the patented product began in 2022, the cumulative sales revenue has reached approximately $100 million. | The stock traded up over 35% in the pre-market in reaction to the news. | | The $0.80 area has acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $0.90, $1, $1.10 and then the after-hours high at $1.18. Beyond that, $1.27, $1.40 and $1.60 come into play. | Below $0.80, targets to the downside are $0.74, $0.70 and then a gap fill at $0.5994. | | ALNY - Up over 30% in the pre-market after reporting positive Phase 3 results for Vutrisan, reducing mortality and recurrent cardiovascular events | Alnylam Pharmaceuticals Inc. (ALNY) is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. | In the pre-market this morning, the company announced that it had achieved positive Phase 3 results for Vutrisan, reducing mortality and recurrent cardiovascular events. | Highlights from the study include: | -Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations | -Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy Populations, Respectively | -Reduced All-Cause Mortality by 36% and 35% in the Overall and Monotherapy Populations, Respectively, in a Pre-Specified Secondary Endpoint | -Demonstrated Clinically Significant Benefits on 6-Minute Walk Test, Kansas City Cardiomyopathy Questionnaire and NYHA Class – Key Measures of Disease Progression | The stock traded up over 30% in the pre-market in reaction to the positive Phase 3 results. | | The first target for bulls is the pre-market high at $235. | Beyond that, is all-time highs at $242.97 and then blue sky above that. | Below $235, targets to the downside are $220, $215, $200 and then $180. | | MARKET NEWS 📰 | | | 👊 Make sure you are getting my mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.” | Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received sixty thousand dollars (cash) from Shore Thing Media for advertising HUB Cyber Security Ltd for a five day marketing program starting on June 17, 2024. This amount was paid by someone else not connected to HUB Cyber Security Ltd. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into HUB Cyber Security Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
